Literature DB >> 19783893

Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients.

E Mannucci1, L Pala, M Monami, L Da Vico, G Bardini, I Dicembrini, S Ciani, C Lamanna, N Marchionni, C M Rotella.   

Abstract

BACKGROUND: The impaired response of glucagonlike peptide-1 (GLP-1) to meals in diabetic patients can contribute to the pathogenesis of impaired insulin secretion and post-prandial hyperglycemia. This study is aimed at the assessment of the relationship between meal-induced GLP-1 and post-prandial hyperglycemia in Type 2 diabetic patients.
METHODS: Twenty-one drug-naïve Type 2 diabetic patients were studied. Blood glucose and active GLP-1 levels were measured 0, 30, 60, 90, and 120 min after a standard test meal. A continuous glucose monitoring (CGM) system was applied for the following 3 days. Nutrient intake at each meal was calculated on the basis of patients' food records. For each patient, post-prandial 120-min glucose incremental area under the curve (iAUC) was included in linear regression model exploring its relationship with total energy and carbohydrate intake, and the angular coefficient for total energy (EAC) and carbohydrate (CAC) was calculated.
RESULTS: GLP-1 levels peaked 30 min after the test meal. Logarithmically transformed 60-min GLP-1 iAUC showed a significant inverse correlation with glycated hemoglobin (HbA1c) (p<0.01). A significant inverse correlation of 60-min GLP-1 iAUC was also observed with EAC and CAC (both p<0.01), meaning that patients with a lower GLP-1 response to the test meal had a higher increment of post-prandial glucose for each additional unit of total energy or carbohydrate intake.
CONCLUSIONS: In Type 2 diabetic patients, a lower GLP-1 response to meals is associated with a higher HbA1c, and with a greater degree of meal-induced hyperglycemia, both in a meal test and during CGM in "real-life" conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783893     DOI: 10.1007/bf03346573

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  14 in total

Review 1.  The MiniMed Continuous Glucose Monitoring System (CGMS).

Authors:  J Mastrototaro
Journal:  J Pediatr Endocrinol Metab       Date:  1999       Impact factor: 1.634

2.  Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

Authors:  C M Edwards; J F Todd; M Mahmoudi; Z Wang; R M Wang; M A Ghatei; S R Bloom
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

3.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

Authors:  T Vilsbøll; T Krarup; C F Deacon; S Madsbad; J J Holst
Journal:  Diabetes       Date:  2001-03       Impact factor: 9.461

4.  Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

Authors:  Jakob Ryskjaer; Carolyn F Deacon; Richard D Carr; Thure Krarup; Sten Madsbad; Jens Holst; Tina Vilsbøll
Journal:  Eur J Endocrinol       Date:  2006-09       Impact factor: 6.664

Review 5.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

6.  Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Authors:  M B Toft-Nielsen; S Madsbad; J J Holst
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

7.  Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.

Authors:  E Mannucci; L Pala; S Ciani; G Bardini; A Pezzatini; I Sposato; F Cremasco; A Ognibene; C M Rotella
Journal:  Diabetologia       Date:  2005-04-29       Impact factor: 10.122

8.  Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus.

Authors:  E Mannucci; A Ognibene; F Cremasco; G Bardini; A Mencucci; E Pierazzuoli; S Ciani; A Fanelli; G Messeri; C M Rotella
Journal:  Diabet Med       Date:  2000-10       Impact factor: 4.359

Review 9.  Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.

Authors:  Michael A Nauck; Birgit Baller; Juris J Meier
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

10.  Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.

Authors:  E Mannucci; A Ognibene; F Cremasco; G Bardini; A Mencucci; E Pierazzuoli; S Ciani; G Messeri; C M Rotella
Journal:  Diabetes Care       Date:  2001-03       Impact factor: 19.112

View more
  4 in total

Review 1.  Ramadan and Diabetes: A Narrative Review and Practice Update.

Authors:  Syed H Ahmed; Tahseen A Chowdhury; Sufyan Hussain; Ateeq Syed; Ali Karamat; Ahmed Helmy; Salman Waqar; Samina Ali; Ammarah Dabhad; Susan T Seal; Anna Hodgkinson; Shazli Azmi; Nazim Ghouri
Journal:  Diabetes Ther       Date:  2020-09-09       Impact factor: 2.945

2.  Impact of incretin on early-phase insulin secretion and glucose excursion.

Authors:  Jie Shen; Zhi Chen; Chaofeng Chen; Xiao Zhu; Yajuan Han
Journal:  Endocrine       Date:  2013-01-03       Impact factor: 3.633

Review 3.  From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.

Authors:  Ilaria Dicembrini; Laura Pala; Carlo Maria Rotella
Journal:  Exp Diabetes Res       Date:  2011-06-23

4.  Urine bile acids relate to glucose control in patients with type 2 diabetes mellitus and a body mass index below 30 kg/m2.

Authors:  David R Taylor; Jamshid Alaghband-Zadeh; Gemma F Cross; Sohail Omar; Carel W le Roux; Royce P Vincent
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.